Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

Covid-19 and Acute Respiratory Distress Syndrome (ARDS) a Clinical Review

Shuofeng Yuan

The COVID-19 pandemic is a serious problem of the new era. Acute respiratory distress syndrome (ARDS) and respiratory failure are the major lung diseases in COVID-19 patients. Although a COVID-19 vaccine is now available, there is still an urgent need to find potential treatments to reduce the impact of her COVID-19 on already sick patients. Several experimental drugs have been approved by the FDA, but their efficacy and possible side effects are unknown. An increasing number of studies worldwide investigating potential COVID-19-related therapies may help identify effective ARDS treatments. This review article first provides an overview of the immunopathology of ARDS. He then outlines the management of his COVID-19 patient requiring intensive care unit (ICU), focusing on current treatment strategies being evaluated in clinical trials for patients with COVID-19-induced ARDS.